NASDAQ:ICU - Nasdaq - US81256L2034 - Common Stock - Currency: USD
1.26
-0.02 (-1.56%)
The current stock price of ICU is 1.26 USD. In the past month the price decreased by -42.73%. In the past year, price decreased by -88.55%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 26.96 | 223.47B | ||
ISRG | INTUITIVE SURGICAL INC | 67.35 | 184.36B | ||
BSX | BOSTON SCIENTIFIC CORP | 37.74 | 150.72B | ||
SYK | STRYKER CORP | 29.95 | 139.34B | ||
MDT | MEDTRONIC PLC | 15.76 | 107.94B | ||
BDX | BECTON DICKINSON AND CO | 14.74 | 58.89B | ||
EW | EDWARDS LIFESCIENCES CORP | 29.25 | 44.70B | ||
IDXX | IDEXX LABORATORIES INC | 38.88 | 35.45B | ||
RMD | RESMED INC | 25.98 | 34.64B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 15.24 | 31.33B | ||
DXCM | DEXCOM INC | 43.43 | 28.10B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 15.94 | 23.53B |
Seastar Medical Holding Corp. operates as a holding company whose subsidiaries manufacture and supply medical devices. The company is headquartered in Denver, Colorado and currently employs 19 full-time employees. The company went IPO on 2021-01-26. The Company’s Selective Cytopheretic Device (SCD) is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. The company has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases. Its SCD therapy is an extracorporeal synthetic membrane device designed to bind activated leukocytes (neutrophils and monocytes) when integrated into an existing continuous renal replacement therapy (CRRT) circuit in conjunction with the use of regional citrate anticoagulation (RCA).
SEASTAR MEDICAL HOLDING CORP
3513 Brighton Blvd, Suite 410
Denver COLORADO US
Employees: 12
Company Website: https://seastarmedical.com
Investor Relations: https://investors.seastarmedical.com/overview/default.aspx
Phone: 18444278100
The current stock price of ICU is 1.26 USD. The price decreased by -1.56% in the last trading session.
The exchange symbol of SEASTAR MEDICAL HOLDING CORP is ICU and it is listed on the Nasdaq exchange.
ICU stock is listed on the Nasdaq exchange.
5 analysts have analysed ICU and the average price target is 7.14 USD. This implies a price increase of 466.67% is expected in the next year compared to the current price of 1.26. Check the SEASTAR MEDICAL HOLDING CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
SEASTAR MEDICAL HOLDING CORP (ICU) has a market capitalization of 10.99M USD. This makes ICU a Nano Cap stock.
SEASTAR MEDICAL HOLDING CORP (ICU) currently has 12 employees.
SEASTAR MEDICAL HOLDING CORP (ICU) has a resistance level at 1.27. Check the full technical report for a detailed analysis of ICU support and resistance levels.
The Revenue of SEASTAR MEDICAL HOLDING CORP (ICU) is expected to grow by 358.72% in the next year. Check the estimates tab for more information on the ICU EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ICU does not pay a dividend.
SEASTAR MEDICAL HOLDING CORP (ICU) will report earnings on 2025-05-12.
SEASTAR MEDICAL HOLDING CORP (ICU) does not have a PE ratio as the earnings reported over the last twelve months were negative (-7.78).
The outstanding short interest for SEASTAR MEDICAL HOLDING CORP (ICU) is 6.32% of its float. Check the ownership tab for more information on the ICU short interest.
ChartMill assigns a fundamental rating of 1 / 10 to ICU. ICU has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months ICU reported a non-GAAP Earnings per Share(EPS) of -7.78. The EPS increased by 52.48% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -533.06% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 80% to ICU. The Buy consensus is the average rating of analysts ratings from 5 analysts.
For the next year, analysts expect an EPS growth of 80.14% and a revenue growth 358.72% for ICU